8 rows
25 mg via Oral
Reported in 8 dose rows. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Oral
Psilocybin clinical studies for Substance Use Disorders (SUD) include 22 structured dose rows across 16 linked trials. Common source-reported dose patterns include 25 mg, 0.1 mg/kg, 0.3 mg/kg. Interpret these as descriptive trial protocols, not treatment recommendations.
This page summarizes source-structured dosing used in linked human clinical studies. It preserves the source-reported unit, route, frequency, and regimen notes where available.
Patterns group structured dose rows with the same reported dose, route, and regimen type. They preserve source units and do not imply clinical equivalence.
Reported in 8 dose rows. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Oral
Reported in 1 dose row. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Oral
Reported in 1 dose row. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Oral
Reported in 1 dose row. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Oral
Reported in 1 dose row. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Oral
Reported in 1 dose row. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Oral
Reported in 1 dose row. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Oral
Reported in 1 dose row. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Oral
Each row comes from a linked clinical trial intervention. Rows with missing or reviewed-incomplete dosing stay visible instead of being filled by inference.
| Study | Arm | Dose | Route and regimen | Source status |
|---|---|---|---|---|
A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence | Psilocybin Psilocybin | 25-40 mg | Oral | flexible two sessions | 2 doses Dose expressed per 70 kg; initial 25 mg/70 kg at session 1, second session may be 25, 30, or 40 mg/70 kg. | Not reviewed existing-data | percentage-of-heavy-drinking-days-following-psilocybin-assisted-psychotherapy-vs |
A Study of Psilocybin for Major Depressive Disorder (MDD) | Psilocybin Psilocybin | 25 mg | Oral single dose | 1 dose Encapsulated synthetic psilocybin; administered with SaS protocol. | Not reviewed existing-data | single-dose-psilocybin-treatment-for-major-depressive-disorder-a-randomized-clin |
Assessing the subjective intensity of oral psilocybin in patients with treatment-resistant depression: a pilot study (PSILODEP-PILOT) | Psilocybin Psilocybin | 10-25 mg | Oral | multi-dose two sessions | 2 doses Two oral doses: 10 mg and 25 mg, separated by one week. | Not reviewed existing-data | psilocybin-with-psychological-support-for-treatment-resistant-depression-an-open |
Clinical and Mechanistic Effects of Psilocybin in Alcohol Addicted Patients | Psilocybin 25 mg Psilocybin | 25 mg | Oral single dose | 1 dose Single oral capsule (25 mg). | Not reviewed existing-data | psilocybin-assisted-therapy-for-relapse-prevention-in-alcohol-use-disorder-a-pha |
Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence | Psilocybin Psilocybin | 0.3-0.4 mg/kg | Oral | multi-dose two sessions | 2 doses Two doses (0.3 mg/kg and 0.4 mg/kg) given in separate all-day sessions 4 weeks apart; delivered with 12-session MET including preparation and debriefing. | Not reviewed existing-data | psilocybin-assisted-treatment-for-alcohol-dependence-a-proof-of-concept-study |
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression | Psilocybin high Psilocybin | 25 mg | Oral | flexible two sessions | 2 doses Sequences: 25 mg at session1 then 5 mg at session2, or 25 mg at both sessions | Not reviewed existing-data | methodological-challenges-in-psychedelic-drug-trials-efficacy-and-safety-of-psil |
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression | Psilocybin low Psilocybin | 5 mg | Oral | multi-dose two sessions | 2 doses Session 1: 5 mg; Session 2: 25 mg | Not reviewed existing-data | methodological-challenges-in-psychedelic-drug-trials-efficacy-and-safety-of-psil |
Imperial College London Open-Label Psilocybin Pilot for Treatment-Resistant Depression (Carhart-Harris / Lyons 2016–2018) | TRD patients Psilocybin | 10 mg | Oral | fixed single dose | 1 dose Initial safety dose | Not reviewed existing-data | psilocybin-with-psychological-support-improves-emotional-face-recognition-in-tre |
Imperial College London Open-Label Psilocybin Pilot for Treatment-Resistant Depression (Carhart-Harris / Lyons 2016–2018) | TRD patients Psilocybin | 25 mg | Oral | fixed single dose | 1 dose Subsequent treatment dose administered 1 week after the first dose | Not reviewed existing-data | psilocybin-with-psychological-support-improves-emotional-face-recognition-in-tre |
Pilot Trial of Visual Healing in Psilocybin-assisted Therapy for Alcohol Use Disorder | Standard setting Psilocybin | 25 mg | Oral two sessions | 2 doses Standard set-and-setting; second session at 4 weeks (participant may choose Visual Healing or standard). | Not reviewed existing-data | nature-themed-video-intervention-may-improve-cardiovascular-safety-of-psilocybin |
Pilot Trial of Visual Healing in Psilocybin-assisted Therapy for Alcohol Use Disorder | Visual Healing Psilocybin | 25 mg | Oral two sessions | 2 doses First session with Visual Healing; second session at 4 weeks (participant may choose Visual Healing or standard). | Not reviewed existing-data | nature-themed-video-intervention-may-improve-cardiovascular-safety-of-psilocybin |
Psilocybin – Induced Neuroplasticity in the Treatment of Major Depressive Disorder | Low dose psilocybin Psilocybin | 0.1 mg/kg | Oral single dose | 1 dose 0.1 mg/kg oral capsule | Not reviewed existing-data | sub-acute-effects-of-psilocybin-on-eeg-correlates-of-neural-plasticity-in-major- |
Psilocybin – Induced Neuroplasticity in the Treatment of Major Depressive Disorder | Medium dose psilocybin Psilocybin | 0.3 mg/kg | Oral single dose | 1 dose 0.3 mg/kg oral capsule | Not reviewed existing-data | sub-acute-effects-of-psilocybin-on-eeg-correlates-of-neural-plasticity-in-major- |
Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use | Psilocybin Psilocybin | 40 mg | Oral single dose Participants undergo two dosing sessions (baseline and 3 months); active-first participants receive 40 mg at baseline; second dosing at 3 months varies per randomisation. | Not reviewed existing-data | psilocybin-for-opioid-use-disorder-in-two-adults-stabilized-on-buprenorphine-a-t |
Psilocybin for Treatment-Resistant Depression | Delayed treatment Psilocybin | 25 mg | Oral single dose, repeat dosing if relapse criteria met | 3 doses Fixed 25 mg oral psilocybin. Participants who relapsed could receive up to two repeat doses, for a total of up to three dosing sessions. | Not reviewed existing-data | psilocybin-assisted-psychotherapy-for-treatment-resistant-depression-a-randomize |
Psilocybin for Treatment-Resistant Depression | Immediate treatment Psilocybin | 25 mg | Oral single dose, repeat dosing if relapse criteria met | 3 doses Fixed 25 mg oral psilocybin. Participants who relapsed could receive up to two repeat doses, for a total of up to three dosing sessions. | Not reviewed existing-data | psilocybin-assisted-psychotherapy-for-treatment-resistant-depression-a-randomize |
Psilocybin in Alcohol Use Disorder With Comorbid Depression (PAD) | Psilocybin 1 mg (control) Psilocybin | 1 mg | Oral two sessions | 2 doses Inactive psilocybin control (1 mg) administered on same schedule; same accompaniment and assessments. | Not reviewed existing-data | psilocybin-in-alcohol-use-disorder-and-comorbid-depressive-symptoms-results-from |
Psilocybin in Alcohol Use Disorder With Comorbid Depression (PAD) | Psilocybin 25 mg Psilocybin | 25 mg | Oral two sessions | 2 doses Two administrations 3 weeks apart; patient accompanied during session (~6 hours); preparation day before and integration day after. | Not reviewed existing-data | psilocybin-in-alcohol-use-disorder-and-comorbid-depressive-symptoms-results-from |
Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors | Group therapy + psilocybin Psilocybin | Needs review | Oral single dose One individual oral psilocybin treatment session; dose not stated in registry fragment. Supplement is not parsed as PDF: paper:psilocybin-assisted-group-therapy-for-demoralized-older-long-term-aids-survivor- / Supplement 1 | Supplement is not parsed as PDF: paper:psilocybin-assisted-group-therapy-for-demoralized-older-long-... | Needs Review needs-review | psilocybin-assisted-group-therapy-and-attachment-observed-reduction-in-attachmen |
Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study | Psilocybin-assisted Psilocybin | 30 mg | Oral | fixed single dose | 1 dose 30 mg per 70 kg; single day-long session | Not reviewed existing-data | psilocybin-or-nicotine-patch-for-smoking-cessation-a-pilot-randomized-clinical-trial |
Psilocybin-facilitated Treatment for Cocaine Use | Psilocybin Psilocybin | 0.36 mg/kg | Oral single dose | 1 dose Single oral dose administered during an 8-hour session; paired with CBT preparation and integration. | Not reviewed existing-data | psilocybin-in-the-treatment-of-cocaine-use-disorder-a-randomized-clinical-trial |
Safety, tolerability, and feasibility of psilocybin-facilitated treatment for methamphetamine use disorder: A pilot study (Psi-MA) | Psilocybin + therapy Psilocybin | 25 mg | Oral single dose | 1 dose 25 mg oral capsule administered 1–2 days after last preparatory session; supervised dosing day (~8 hours). | Not reviewed existing-data | psilocybin-assisted-psychotherapy-for-methamphetamine-use-disorder-a-pilot-open- |